Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Dai ichi Life Insurance Company Ltd

Dai ichi Life Insurance Company Ltd lowered its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 11.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 955 shares of the biopharmaceutical company’s stock after selling 122 shares during the period. Dai ichi Life Insurance Company Ltd’s holdings in Alnylam Pharmaceuticals were worth $263,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Huntington National Bank increased its stake in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares in the last quarter. Hollencrest Capital Management acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter worth about $29,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $26,000. Washington Trust Advisors Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $42,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $45,000. 92.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the sale, the executive vice president now owns 13,191 shares in the company, valued at $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CMO Pushkal Garg sold 1,682 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the transaction, the chief marketing officer now owns 17,457 shares of the company’s stock, valued at approximately $4,381,357.86. This represents a 8.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 8,370 shares of company stock valued at $2,100,703 in the last quarter. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 0.2 %

Shares of ALNY stock opened at $253.74 on Friday. The stock has a 50 day moving average of $271.93 and a 200-day moving average of $240.19. The firm has a market cap of $32.73 billion, a PE ratio of -96.85 and a beta of 0.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. Alnylam Pharmaceuticals’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.15 earnings per share. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. StockNews.com cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Piper Sandler reissued an “overweight” rating and issued a $296.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Raymond James boosted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Finally, Bank of America increased their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $298.09.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.